Pfizer said today it would generate $1.7 billion more in savings from cost-cutting to its manufacturing and research operations and reported lower first-quarter revenue due to declining sales of its Paxlovid Covid-19 treatment.
Full Story
3,123,000 news articles indexed and analysed from 346 sources in 4 languages.
Articles and images are sorted, ranked and categorised automatically, placement is not intended to cause offence.
WireBeat accepts no liability for the content published by third parties.
English ¦ 
Spanish ¦ 
French ¦ 
German
© Accumudata Limited 2022 Release Version 1.22 Company Number: 12846061 All Rights Reserved.